TVTX – travere therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Travere Therapeutics to Report First Quarter 2024 Financial Results
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at HC Wainwright from $17.00 to $19.00. They now have a "buy" rating on the stock.
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy [Yahoo! Finance]
Form SC 13G Travere Therapeutics, Filed by: Rock Springs Capital Management LP
Form 8-K Travere Therapeutics, For: Apr 24
Form 4 Travere Therapeutics, For: Apr 11 Filed by: Cline Christopher R.
Form ARS Travere Therapeutics, For: Dec 31
Form DEFA14A Travere Therapeutics,
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.